Nasdaq Pharmaceutical Stocks Drop 6% Despite New Drug Optimism and Buy Ratings

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) closed at $13.10 on the Nasdaq on the 19th, down 5.82%. Trading volume was about 1.21 million shares, and its market capitalization fell to roughly $4.2 billion (around KRW 5.9 trillion), wiping out approximately $230 million (KRW 320 billion) in value in a single session.

Yesterday, UBS initiated coverage on AMRX with a Buy rating and a $19 price target, yet the shares—already down about 14% over the past two months—continued to slide today. On the same day, Amneal reported positive interim results from its Phase 4 ELEVATE-PD trial of Crexont for Parkinson’s disease, showing an increase in daily “good motor time.” Despite the clinical upside, the stock’s performance remains muted.

Headquartered in Bridgewater, New Jersey, Amneal is a generics- and biosimilars-focused pharmaceutical company. It has built its business around low-cost generics, complex formulations, biosimilars, and specialist drugs for central nervous system and endocrine disorders. The company’s operations are structured into Affordable Medicines (generics), Branded Pharmaceuticals, and AvKARE, which handles U.S. federal and institutional distribution—segments that together drive the majority of its U.S. revenue.